Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.

Published

Journal Article

BACKGROUND: Although aspirin is beneficial in patients with unstable angina, it is a relatively weak inhibitor of platelet aggregation. The effect of Integrelin, which inhibits the platelet fibrinogen receptor glycoprotein (GP) IIb/IIIa, on the frequency and duration of Holter ischemia was evaluated in 227 patients with unstable angina. METHODS AND RESULTS: Patients received intravenous heparin and standard ischemic therapy and were randomized to receive oral aspirin and placebo Integrelin; placebo aspirin and low-dose Integrelin. 45 micrograms/kg bolus followed by a 0.5 microgram.kg-1. min-1 continuous infusion; or placebo aspirin and high-dose Integrelin, 90 micrograms/kg bolus followed by a 1.0-microgram.kg-1, min-1 constant infusion. Study drug was continued for 24 to 72 hours, and Holter monitoring was performed. Patients randomized to high-dose Integrelin experienced 0.24 +/- 0.11 ischemic episodes (mean +/- SEM) on Holter lasting 8.41 +/- 5.29 minutes over 24 hours of study drug infusion. Patients randomized to aspirin experienced a greater number (1.0 +/- 0.33, P < .05) and longer duration (26.2 +/- 9.8 minutes, P = .01) of ischemic episodes than the high-dose Integrelin group. There was no evidence of rebound ischemia after withdrawal of study drug. In 46 patients, platelet aggregation was rapidly inhibited by Integrelin in a dose-dependent fashion. The number of clinical events was small, and there were no bleeding differences in the three treatment arms. CONCLUSIONS: Intravenous Integrelin is well tolerated, is a potent reversible inhibitor of platelet aggregation, and added to full-dose heparin reduces the number and duration of Holter ischemic events in patients with unstable angina compared with aspirin.

Full Text

Duke Authors

Cited Authors

  • Schulman, SP; Goldschmidt-Clermont, PJ; Topol, EJ; Califf, RM; Navetta, FI; Willerson, JT; Chandra, NC; Guerci, AD; Ferguson, JJ; Harrington, RA; Lincoff, AM; Yakubov, SJ; Bray, PF; Bahr, RD; Wolfe, CL; Yock, PG; Anderson, HV; Nygaard, TW; Mason, SJ; Effron, MB; Fatterpacker, A; Raskin, S; Smith, J; Brashears, L; Gottdiener, P; du Mee, C; Kitt, MM; Gerstenblith, G

Published Date

  • November 1, 1996

Published In

Volume / Issue

  • 94 / 9

Start / End Page

  • 2083 - 2089

PubMed ID

  • 8901655

Pubmed Central ID

  • 8901655

International Standard Serial Number (ISSN)

  • 0009-7322

Digital Object Identifier (DOI)

  • 10.1161/01.cir.94.9.2083

Language

  • eng

Conference Location

  • United States